Loading
SELLAS Life Sciences Group, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Kalin Katherine Bach, was filed 21 Nov 2025.
Insider Decl.
120
Thresholds
n/a
Buy Volume
€161,416
4 ops. · all time
Sell Volume
€2M
10 ops. · all time
Who traded when
BuySaleKatherine Bach Kalin2 buys
Jane Wasman1 buy
Robert L. van Nostrand1 buy
Since the insiders bought
- +167.7%Entry US$1.55 · Close at T+90 US$4.15
- +380.1%Entry US$1.61 · Close at T+365 US$7.73
- +399.4%Entry US$1.64 · Close at T+365 US$8.19
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$9.98
Analyst consensus
2 analysts1.50/5
US$30.00Target US$32.50(+226%)US$35.00
Income statement
EBITDA-US$28.3M
Net income-US$26.9M0.0% margin
Valuation
PER (forward)-99.8x
P/Book14.6x
Beta2.57
Balance sheet & cash
Market capUS$2B
Total debtUS$1M
Free Cash Flow-US$28.4M
Debt / Equity1%
Profitability & ownership
ROE-39.6%
ROA-23.3%
% insiders0.9%
% institutions37.0%
Last declaration on 9 January 2026
Declarations120 total
50,000 shares0Common StockSEC:0001104659-26-002515:0
50,000 shares0Common StockSEC:0001104659-26-002511:0
50,000 shares0Common StockSEC:0001104659-26-002509:0
300,000 shares0Common StockSEC:0001104659-26-002506:0
300,000 shares0Common StockSEC:0001104659-26-002502:0
50,000 shares0Common StockSEC:0001104659-26-002499:0
50,000 shares0Common StockSEC:0001104659-26-002491:0
63,800 shares@ US$1.5090.3% of flowCommon StockSEC:0001104659-25-118882:0
58,592 shares@ US$1.5083.7% of flowCommon StockSEC:0001104659-25-118878:0
187,066 shares@ US$1.5077.4% of flowCommon StockSEC:0001104659-25-118872:0
63,400 shares@ US$1.5973.2% of flowCommon StockSEC:0001104659-25-114806:0
Canonical exit: 17 Feb 2026 (T+90)
10,000 shares@ US$1.48100.0% of flowCommon StockSEC:0001104659-25-059166:0
Canonical exit: 10 Sept 2025 (T+90)
20,000 shares@ US$1.69100.0% of flowCommon StockSEC:0001104659-25-055495:0
Canonical exit: 28 Aug 2025 (T+90)
20,000 shares@ US$1.8026.8% of flowCommon StockSEC:0001104659-25-051980:0
Canonical exit: 20 Aug 2025 (T+90)
81,300 shares0Common StockSEC:0001104659-25-003502:1
243,900 shares0Common StockSEC:0001104659-25-003501:1
81,300 shares0Common StockSEC:0001104659-25-003494:1
113,000 shares0Common StockSEC:0001104659-25-003502:0
113,000 shares0Common StockSEC:0001104659-25-003494:0
12,500 shares0Common StockSEC:0001104659-25-003496:0
257,000 shares0Common StockSEC:0001104659-25-003501:0
12,500 shares0Common StockSEC:0001104659-25-003495:0
12,500 shares0Common StockSEC:0001104659-25-003499:0
12,500 shares0Common StockSEC:0001104659-25-003497:0
12,500 shares0Common StockSEC:0001104659-25-003498:0
25 of 120 declarations
About SELLAS Life Sciences Group, Inc.
Amounts are modest at SELLAS Life Sciences Group, Inc., a US healthcare company valued at USD 2 billion: 10 sales worth EUR 2.2 million, with a median of EUR 8,498, and 4 purchases worth EUR 161,416 (median EUR 30,808). The largest trade is a sale by Hudson Bay Capital Management LP, a 10% owner, of EUR 1,859,225 on February 8, 2017. Ryan Dunlap, former Chief Financial Officer, sold EUR 247,195 on June 1, 2016, and Angelos M. Stergiou (President and CEO) EUR 25,434 on December 31, 2018.
The four purchases are recent and come from directors: Katherine Bach Kalin for EUR 87,043 on November 19, 2025 and EUR 31,910 on May 22, 2025, and Jane Wasman for EUR 29,705 on May 30, 2025. From May 22 to June 12, 2025, three insiders bought EUR 74,373.
Read moreShow less
The record has 120 filings from 23 filers, 87 of them grants. John Thomas Burns (CFO) files 14 and Stergiou 13. Annual volume reaches 39 in 2017 then 18 in 2025. Insiders hold 0.9% of the capital. The last twelve months have 11 filings, 1 of them a purchase.
